Interindividual variation in transdermal and oral drug deliveries

Journal of Pharmaceutical Sciences

Volumn 101, Issue 11, 2012, Pages 4293-4307

  Levin, Jacquelyn ^a   Maibach, Howard ^b  

^a Largo Medical Center   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Drug delivery systems; Drug transport; Interindividual Variation; Oral absorption; Oral drug delivery; Partition coefficient.; Percutaneous absorption; Pharmacokinetics pharmacodynamics; Transdermal; Transdermal drug delivery

Indexed keywords

CLONIDINE; ESTRADIOL; GLYCERYL TRINITRATE; LEVONORGESTREL; NICOTINE; NORELGESTROMIN; OXYBUTYNIN; RIVASTIGMINE; SELEGILINE; TESTOSTERONE;

AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; HUMAN; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; NONHUMAN; REVIEW;

EID: 84866432605     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23270     Document Type: Article

References (60)

1. Appell RA, Chancellor MB, Zobrist RH, Thomas H, Sanders SW. 2003. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc 78(6):696-702.
2. Douchamps J, Derenne F, Stockis A, Gangji D, Juvent M, Herchuelz A. 1988. The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol 35(5):515-520.
3. Zobrist RH, Schmid B, Feick A, Quan D, Sanders SW. 2001. Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharm Res 18(7):1029-1034.
4. Zobrist RH, Quan D, Thomas HM, Stanworth S, Sanders SW. 2003. Pharmacokinetics and metabolism of transdermal oxybutynin: In vitro and in vivo performance of a novel delivery system. Pharm Res 20(1):103-109.
5. Tanner T, Marks R. 2008. Delivering drugs by the transdermal route: Review and comment. Skin Res Technol 14(3):249-260.
6. Cusack BJ. 2004. Pharmacokinetics in older persons. Am J Geriatr Pharmacother 2:274-302.
7. Devineni D, Skee D, Vaccaro N, Massarella J, Janssens L, LaGuardia KD, Leung AT. 2007. Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive. J Clin Pharmacol 47(4):497-509.
8. Järvinen A, Nykänen S, Paasiniemi L. 1999. Absorption and bioavailability of oestradiol from a gel, a patch and a tablet. Maturitas 32(2):103-113.
9. Abrams LS, Skee DM, Natarajan J, Wong FA, Anderson GD. 2002. Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinyloestradiol at four application sites. Br J Clin Pharmacol 53(2):141-146.
10. Alikhan A, Farahmand S, Maibach HI. 2009. Correlating percutaneous absorption with physicochemical parameters in vivo in man: Agricultural, steroid, and other organic compounds. J Appl Toxicol 29(7):590-596.
11. Feldmann RJ, Maibach HI. 1969. Percutaneous penetration of steroids in man. J Invest Dermatol 52(1):89-94.
12. Feldmann RJ, Maibach HI. 1970. Absorption of some organic compounds through the skin in man. J Invest Dermatol 54(5):399-404.
13. Farahmand S, Maibach HI. 2009. Transdermal drug pharmacokinetics in man: Interindividual variability and partial prediction. Int J Pharm 367(1-2):1-15.
14. Sobue S, Sekiguchi K, Kikkawa H, Akasaki M, Irie S. 2006. Comparison of nicotine pharmacokinetics in healthy Japanese male smokers following application of the transdermal nicotine patch and cigarette smoking. Biol Pharm Bull 29:1068-1073.
15. Gupta SK, Okerholm RA, Eller M, Wei G, Rolf CN, Gorsline J. 1995. Comparison of the pharmacokinetics of two nicotine transdermal systems: Nicoderm and habitrol. J Clin Pharmacol 35:493-498.
16. Gupta SK, Okerholm RA, Coen P, Prather RD, Grosline J. 1993. Single- and multiple-dose pharmacokinetics of Nicoderm (nicotine transdermal system). J Clin Pharmacol 33:169-174.
17. Prather RD, Tu TG, Rolf CN, Grosline J. 1993. Nicotine pharmacokinetics of Nicoderm (nicotine transdermal system) in women and obese men compared with normal-sized men. J Clin Pharmacol 33:644-649.
18. Bur A, Joukhadar C, Klein N, Herkner G, Mitulovic R, Schmid E, Agneter M, Müller M, Brunner. 2005. Effect of exercise on transdermal nicotine release in healthy habitual smokers. Int J Clin Pharmacol Ther 43:239-243.
19. Bannon YB, Corish J, Corrigan OI, Devane JG, Kavanagh M, Mulligan S. 1989. Transdermal delivery of nicotine in normal human volunteers: A single dose and multiple dose study. Eur J Clin Pharmacol 37:285-290.
20. Fant RV, Henningfield JE, Shiffman S, Strahs KR, Reitberg DP. 2000. A pharmacokinetic crossover study to compare the absorption characteristics of three transdermal nicotine patches. Pharmacol Biochem Behav 67:479-482.
21. Physician's Desk Reference. 2006. 60th ed. New Jersey: Thompson PDR.
22. Amory JK, Kalhorn TF, Page ST. 2008. Pharmacokinetics and pharmacodynamics of oral testosterone enanthate plus dutasteride for 4 weeks in normal men: Implications for male hormonal contraception. J Androl 29:260-271.
23. Buch AB, Shen LZ, Kelly SC, Russell DA, Sahota RS, Bixler CA, Moehrke W, Powell JH. 1999. Significant differences in estradiol bioavailability from two similarly labelled estradiol matrix transdermal systems. Climacteric 2:248-253.
24. Baracat E, Haidar M, Castelo A, Tufik S, de Lima GR, Vieira JG, Peloso U, Casoy J. 1996. Comparative bioavailability study of a once-a-week matrix versus a twice-a-week reservoir transdermal estradiol delivery systems in postmenopausal women. Maturitas 23:285-291.
25. Harrison LL, Harari D. 2002. An evaluation of bioequivalence of two 7-day 17betaestradiol transdermal delivery systems by anatomical site. J Clin Pharmacol 42:1134-1141.
26. Rohr UD, Nauert C, Stehle B. 1999. 17Beta-estradiol delivered by three different matrix patches 50 microg/day: A three way cross-over study in 21 postmenopausal women. Maturitas 33:45-58.
27. Reginster JY, Albert A, Deroisy R, Colette J, Vrijens B, Blacker C, Brion N, Caulin F, Mayolle C, Regnard A, Scholler R, Franchimont P. 1997. Plasma estradiol concentrations and pharmacokinetics following transdermal application of Menorest 50 or Systen (Evorel) 50. Maturitas 1997; 27:179-186.
28. Hossain M, Quebe-Fehling E, Sergejew T, Schmidt G, Skerjanec A, Ibarra de Palacios P, Krinsky L. 2003. Dose proportionality study of four doses of an estradiol transdermal system. Estradot. Maturitas 46:173-185.
29. Hossain M, Quebe-Fehling E, Sergejew T, Schmidt G, Skerjanec A, Cohen A, Krinsky L, Ibarra de Palacios P. 2003. Comparative bioequivalence studies with Estradot and Menorest transdermal systems. Maturitas 46:187-198.
30. Boyd RA, Zegarac EA, Eldon MA, Sedman AJ, Forgue ST. 1996. Characterization of a 7 day 17 beta-estradiol transdermal delivery system: Pharmacokinetics in healthy postmenopausal women. Biopharm Drug Dispos 17:459-470.
31. Guichard JP, Sauron R, Jones AB. 1999. Comparison of the pharmacokinetics of 17 beta-estradiol after a single 4-day application of Oesclim 50, Oesclim 100, and Vivelle 0.05 (Menorest 50) transdermal delivery systems. J Clin Pharmacol 39:811-816.
32. Reginster JY, Donazzolo Y, Brion N, Lins R. 2000. Estradiol pharmacokinetics after transdermal application of patches to postmenopausal women: Matrix versus reservoir patches. Climacteric 3:168-175.
33. Meikle AW, Arver S, Dobs AS, Sanders SW, Rajaram L, Mazer NA. 1996. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: Influence of application site-A clinical research center study. J Clin Endocrinol Metab 81:1832-1840.
34. Brocks DR, Meikle AW, Boike SC, Mazer NA, Zariffa N, Audet PR, Jorkasky DK. 1996. Pharmacokinetics of testosterone in hypogonadal men after transdermal delivery: Influence of dose. J Clin Pharmacol 36:732-739.
35. McClellan KJ, Goa KL. 1998. Transdermal testosterone. Drugs 55:253-257, discussion 259.
36. Lefèvre G, Sedek G, Jhee SS, Leibowitz MT, Huang HL, Enz A, Maton S, Ereshefsky L, Pommier F, Schmidl H, Appel-Dingemanse S. 2008. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. Clin Pharmacol Ther 83:106-114.
37. Lefèvre G, Sedek G, Huang HL, Saltzman M, Rosenberg M, Kiese B, Fordham P. 2007. Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: Relative effects of body site application. J Clin Pharmacol 47:471-478.
38. Mercier F, Lefèvre G, Huang HL, Schmidli H, Amzal B, Appel-Dingemanse S. 2007. Rivastigmine exposure provided by a transdermal patch versus capsules. Curr Med Res Opin 23:3199-3204.
39. Harrison LI, Zurth C, Gunther C, Karara AH, Melikian A, Lipp R. 2007. Simultaneous estradiol and levonorgestrel transdermal delivery from a 7-day patch: In vitro and in vivo drug deliveries of three formulations. Drug Dev Ind Pharm 33:373-380.
40. Zacur HA, Hedon B, Mansour D, Shangold GA, Fisher AC, Creasy GW. 2002. Integrated summary of Ortho Evra/Evra contraceptive patch adhesion in varied climates and conditions. Fertil Steril 77:S32-S35.
41. Abrams LS, Skee DM, Natarajan J, Wong FA, Leese PT, Creasy GW, Shangold MM. 2001. Pharmacokinetics of norelgestromin and ethinyl estradiol delivered by a contraceptive patch (Ortho Evra/Evra) under conditions of heat, humidity, and exercise. J Clin Pharmacol 41:1301-1309.
42. Ito MK, O'Connor DT. 1991. Skin pretreatment and the use of transdermal clonidine. Am J Med 91:S42-S49.
43. Fujimura A, Ebihara A, Ohashi K, Shiga T, Kumagai Y, Nakashima H, Kotegawa T. 1994. Comparison of the pharmacokinetics, pharmacodynamics, and safety of oral (Catapres) and transdermal (M-5041T) clonidine in healthy subjects. J Clin Pharmacol 34:260-265.
44. Azzaro AJ, Ziemniak J, Kemper E, Campbell BJ, VanDenBerg C. 2007. Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6mg/24h): A comparison with oral selegiline capsules. J Clin Pharmacol 47(10):1256-1267.
45. Rohatagi S, Barrett JS, DeWitt KE, Morales RJ. 1997. Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration. Biopharm Drug Dispos 18:567-584.
46. Rohatagi S, Barrett JS, McDonald LJ, Morris EM, Darnow J, DiSanto AR. 1997. Selegiline percutaneous absorption in various species and metabolism by human skin. Pharm Res 14:50-55.
47. Yu DK, Williams RL, Benet LZ, Lin ET, Giesing DH. 1998. Pharmacokinetics of nitroglycerin and metabolites in humans following oral dosing. Biopharm Drug Dispos 9:557-565.
48. Ponti FDE, Luca C, Pamparana F. 1989. Bioavailability study of three transdermal nitroglycerin preparations in normal volunteers. Curr Ther Res 46:111-120.
49. Wolff M, Cordes G, Luckow V. 1985. In vitro and in vivo release of nitroglycerin from a new transdermal therapeutic system. Pharm Res 2:23-29.
50. Riedel DJ, Wick KA, Hawkinson RW, Kolars CA, Crowley JK, Armstrong KE, Chang SF, Harrison LI, de Dennis SR. 1989. Performance of a new transdermal nitroglycerin adhesive patch formulation. Clin Ther 11:225-231.
51. Auclair B, Sirois G, Ngoc AH, Ducharme MP. 1998. Novel pharmacokinetic modelling of transdermal nitroglycerin. Pharm Res 15:614-619.
52. Sun JX, Piraino AJ, Morgan JM, Joshi JC, Cipriano A, Chan K, Redalieu E. 1995. Comparative pharmacokinetics and bioavailability of nitroglycerin and its metabolites from Transderm-Nitro, Nitrodisc, and Nitro-Dur II systems using a stable-isotope technique. J Clin Pharmacol 35:390-397.
53. Noonan PK, Gonzalez MA, Ruggirello D, Tomlinson J, Babcock-Atkinson E, Ray M, Golub A, Cohen A. 1986. Relative bioavailability of a new transdermal nitroglycerin delivery system. J Pharm Sci 75:688-691.
54. Auclair B, Sirois G, Ngoc AH, Ducharme MP. 1998. Population pharmacokinetics of nitroglycerin and of its two metabolites after a single 24-hour application of a nitroglycerin transdermal matrix delivery system. Ther Drug Monit 20:607-611.
55. McCarley KD, Bunge AL. 2001. Pharmacokinetic models of dermal absorption. J Pharm Sci 90(11):1699-1719.
56. Oxtoby DW, Nachtrieb NH. 1996. Principles of modern chemistry. 3rd ed. Orlando, Florida: Saunders College Publishing.
57. MacGregor TR, Matzek KM, Keirns JJ, van Wayjen RG, van den Ende A, van Tol RG. 1985. Pharmacokinetics of transdermally delivered clonidine. Clin Pharmacol Ther 38(3):278-284.
58. Gupta SK, Southam M, Gale R, Hwang SS. 1992. System functionality and physicochemical model of fentanyl transdermal system. J Pain Symptom Manage 7(3 Suppl):S17-S26.
59. Grond S, Radbruch L, Lehmann KA. 2000. Clinical pharmacokinetics of transdermal opioids: Focus on transdermal fentanyl. Clin Pharmacokinet 38(1):59-89.
60. Hikima T, Tojo K, Maibach HI. 2005. Skin metabolism in transdermal therapeutic systems. Skin Pharmacol Physiol 18(4):153-159.